Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets
24th July 2024, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5…
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
9thJuly 2024, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.07%. The approved ANDA is therapeutically…
Alembic Pharmaceuticals announces USFDA Tentative Approval for Ivosidenib Tablets 250 mg
4 July 2024, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivosidenib Tablets, 250 mg. The approved ANDA is…
Orchid Pharma assigns PR duties to Cumulus
Gurugram, 05 April 2024: Orchid Pharma (NSE/BSE), a Chennai-based, leading pharmaceutical company catering across the pharmaceutical value chain (discovery to delivery) with expertise in R&D and marketing, has appointed Gurgaon-based Cumulus Public Relations as its official communications partner. After almost…